Software Equity Group

MARCH 21, 2023

There are several resources for growth capital: debt from a lender or financial institution, minority equity financing, or majority equity financing through a control transaction. Several types of debt financing exist , including recurring revenue lending, non-bank cash flow lending, and loans from financial institutions.

Finance 52

Finance Finance Debt Equities 52

Peak Frameworks

SEPTEMBER 19, 2023

Role of Early-stage Financing Financing plays a pivotal role in the startup stage. Businesses typically don't generate a profit at this point, making external financing necessary. Choosing the right exit strategy—be it acquisition, Initial Public Offering (IPO), or management buyout—is critical.

Business 52

Business Finance Finance Private Equity 52

Cooley M&A

MARCH 1, 2019

Pursuing a “dual-track” process involves preparing for an initial public offering at the same time as running a private M&A process, often through an auction. Relative to choosing a single exit strategy, a dual-track process tends to be more complicated and resource-intensive, while also posing some specific risks.

IPO 52

IPO Valuation M&A Business 52

Cooley M&A

APRIL 5, 2024

Background At the center of this case is investment bank Moelis & Company and the stockholder agreement that it entered into with its founder prior to its initial public offering. A “board size requirement” that the board size not exceed 11 members. Ruling and rationale There were three key components to the court’s ruling.

M&A 52

M&A Mergers and Acquisitions Mergers Corporation 52

Cooley M&A

JANUARY 25, 2023

Will 2023 see a resurgence of traditional public M&A deals or will macro factors and the looming threat of regulatory review continue to push biotechnology companies down creative paths? Let’s dig in. Not to be outdone by their US counterparts, regulators outside the US also are taking more interventionist roles in merger review.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 23, 2024

In an environment where licensing deals also present antitrust risk, big pharmaceutical companies may favor M&A instead to have full control over the assets – and make the cost of litigating against the antitrust agencies worth the time and money.

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52

Cooley M&A

JANUARY 30, 2024

Software companies with a target on their backs Public software companies (particularly those with mature revenue growth rates) are often ripe acquisition targets for mega cap tech and highly acquisitive, software focused private equity sponsors, and therefore present easy targets for “sell the company” campaigns by activists.

Private Equity 52

Private Equity M&A Capital Investors 52